Supernus Pharmaceuticals (SUPN) Scheduled to Post Earnings on Monday

Supernus Pharmaceuticals (NASDAQ:SUPN) will be posting its quarterly earnings results after the market closes on Monday, November 4th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.39 per share for the quarter. Supernus Pharmaceuticals has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company had revenue of $168.30 million for the quarter, compared to the consensus estimate of $148.83 million. During the same quarter last year, the company posted ($0.02) EPS. The business’s revenue was up 24.1% compared to the same quarter last year. On average, analysts expect Supernus Pharmaceuticals to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $33.97 on Friday. Supernus Pharmaceuticals has a twelve month low of $23.05 and a twelve month high of $35.56. The stock has a market capitalization of $1.87 billion, a PE ratio of 377.44 and a beta of 0.88. The stock has a 50-day simple moving average of $33.02 and a 200 day simple moving average of $30.44.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.